Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Prostate stem cell antigen (PSCA) is a GPI-anchored cell surface glycoprotein involved in intracellular signaling and potentially acetylcholine receptor regulation. It is overexpressed in several cancers, including prostate, bladder, pancreatic, and NSCLC, and is associated with more aggressive disease. Conversely, it is downregulated in esophageal/gastric cancers, suggesting a possible tumor-suppressive role in those contexts. Due to its restricted expression pattern and overexpression on tumor cells, PSCA is considered a potential target for immunotherapy.
Not applicable; PSCA itself is not a drug, but a target for therapeutic intervention such as immunotherapy or siRNA.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Prostate stem cell antigen (PSCA).